Abveris and Harbour Antibodies H2L2 BV Announce Technology Co-Offering Agreement for Fully Human Antibody Discovery Canton, MA, USA, Cambridge, MA, USA, and Rotterdam, the Netherlands, July 1, 2019 – Abveris, Inc., a global leader in contract research antibody discovery, and Harbour Antibodies H2L2 BV, a wholly-owned subsidiary of Harbour BioMed, today announced a partnership to offer fully-human antibody discovery service that combines Abveris’ antibody discovery services with the Harbour H2L2 human transgenic mouse platform. The combined offering eliminates the need for antibody humanization through the use of the H2L2 Harbour Mice™, and benefits from Abveris’ full suite of therapeutic antibody discovery capabilities. Abveris was selected as a designated CRO to …

Dr. Jung Lee Joins Harbour Antibodies as Vice President of Business Development SHANGHAI & ROTTERDAM, the Netherlands & CAMBRIDGE, Mass. July 13, 2018 Harbour Antibodies US, a subsidiary of Harbour Biomed, announced today that it has appointed Jung Lee, Ph.D. as its Vice President of Business Development. In this role, Dr. Lee will lead the company’s efforts in out-licensing of the H2L2 and HCAb Harbour transgenic mouse platforms and developing strategic collaboration and partnerships in both US and EU. “Dr. Lee’s expertise and experience were a perfect fit for Harbour Antibodies US, as we continue to unlock the vast potential of our transgenic technology platforms and develop new biologics,” said …

LakePharma and Harbour Antibodies Announce Partnership for H2L2 Transgenic Mouse Platform for Therapeutic Antibody Discovery Agreement Provides for Easy Access to H2L2 Platform Use with LakePharma’s Discovery and Development Services BELMONT, Calif. and CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, June 5, 2018 LakePharma and Harbour Antibodies BV, a Harbour BioMed subsidiary, today announced a technology partnership providing LakePharma the right to utilize Harbour Antibodies’ patented, H2L2 transgenic mouse platform in its therapeutic antibody discovery service offerings to clients in pharmaceutical and therapeutic biotechnology companies. Harbour Antibodies’ patented H2L2 transgenic mice produce classical antibodies (two heavy and two light chain immunoglobulins) with fully human variable regions. In response to antigen challenge, the …

Harbour BioMed and The Wistar Institute Join Forces to Advance Novel Antibody Therapies for Cancer and Infectious Diseases Collaboration combines Harbour’s proprietary H2L2 transgenic mouse platform for generating fully human monoclonal antibodies with Wistar’s cancer biology, immunology expertise CAMBRIDGE, Mass. & PHILADELPHIA & SHANGHAI– Harbour BioMed and The Wistar Institute announced today that they have entered into a multi-year, multifaceted research collaboration to co-discover novel antibodies for the treatment of cancer and infectious diseases. This strategic collaboration will leverage Harbour BioMed’s innovative H2L2 platform with Wistar’s fundamental research expertise in cancer biology and immunology to generate fully human monoclonal antibodies directed against unique targets. Harbour BioMed and Wistar will work …